A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Shattuck Labs, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 32,300 shares of STTK stock, worth $124,678. This represents 0.0% of its overall portfolio holdings.

Number of Shares
32,300
Holding current value
$124,678
% of portfolio
0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$7.37 - $10.09 $238,051 - $325,907
32,300 New
32,300 $288,000
Q3 2022

Nov 14, 2022

SELL
$2.6 - $5.52 $37,700 - $80,040
-14,500 Reduced 35.54%
26,300 $71,000
Q2 2022

Aug 15, 2022

SELL
$2.7 - $4.59 $119,340 - $202,878
-44,200 Reduced 52.0%
40,800 $166,000
Q1 2022

May 16, 2022

BUY
$4.22 - $8.89 $178,506 - $376,047
42,300 Added 99.06%
85,000 $362,000
Q4 2021

Feb 14, 2022

BUY
$8.36 - $21.08 $356,972 - $900,115
42,700 New
42,700 $363,000

Others Institutions Holding STTK

About Shattuck Labs, Inc.


  • Ticker STTK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,382,000
  • Market Cap $164M
  • Description
  • Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is ...
More about STTK
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.